NCR3LG1 and breast carcinoma: Similar results were observed when breast cancer cells overexpressing B7H6 (MCF7.B7H6), in which MHC-class I expression was abrogated by CRISPR/Cas9-mediated knockout of B2M (MCF7.B7H6.B2M KO) (Figure 4(e-f)), were used as targets.